The Phase 2 data strongly de-risks INBRX-106 and validates the OX40 agonist mechanism, making this a significant positive catalyst. Traders should watch for FDA alignment on the accelerated approval pathway and the mid-2027 NSCLC readout as the next key milestones. The stock is likely to re-rate upward on the potential to capture the HPV+ HNSCC market.
Price Chart
Executive Summary
Inhibrx reported Phase 2 data for INBRX-106 in 1L HNSCC, showing a 48.3% cORR vs 26.5% for pembrolizumab alone, with a median PFS of 9.6 months vs 4.9 months. The HPV+ subgroup showed an 80.0% cORR and 90.0% PFS6 rate. The company plans to expand the Phase 2 study by ~50 HPV+ patients to pursue an accelerated approval pathway by end of 2028/early 2029. This is a material positive catalyst for the stock, validating the OX40 agonist mechanism and opening a large commercial opportunity.
Key Facts
- INBRX-106 + pembrolizumab achieved 48.3% cORR vs 26.5% for pembrolizumab alone in 1L HNSCC (PD-L1 CPS≥20).
- Median PFS was 9.6 months for the combination vs 4.9 months for pembrolizumab alone.
- In HPV+ patients, cORR was 80.0% vs 33.3%, and PFS6 rate was 90.0% vs 33.0%.
- 30.0% of HPV+ patients on the combination achieved a complete response vs 0% on pembrolizumab alone.
- Inhibrx plans to expand the Phase 2 study by ~50 additional HPV+ OPSCC patients to support a potential accelerated approval pathway by end of 2028/early 2029.
- The company is also evaluating INBRX-106 in peri-operative NSCLC (Phase 1/2) with initial results targeted by mid-2027.
Financial Impact
HPV+ HNSCC is an estimated $4B+ US market opportunity; broader immunogenic tumor expansion targets a $50B+ WW market opportunity.
Risk Factors
- Data are from a Phase 2 study with a small sample size (n=68 randomized, 63 evaluable) and may not be replicated in larger Phase 3 trials.
- The accelerated approval pathway is not guaranteed and requires FDA alignment.
- Competition from other therapies in HNSCC, including EGFR bispecifics and other immunotherapies.
- The company has no approved products and is pre-revenue, with reliance on pipeline success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0002007919-26-000047 |
| Exhibit: exhibit991-pressreleasesep.htm | 0002007919-26-000047 |
| Document: inhibrx-20260908.htm | 0002007919-26-000047 |
| Document: 0002007919-26-000047-index-headers.html | 0002007919-26-000047 |
| Document: 0002007919-26-000047-index.html | 0002007919-26-000047 |
| Document: 0002007919-26-000047.txt | 0002007919-26-000047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Buy | $90.50 | awaiting T+60 | — | $88.61 (−2.09%) |
Sep 28, 2026 27d ago | Insider Cluster | $104.83 | awaiting T+60 | — | $88.61 (−15.47%) |
Sep 17, 2026 5w ago | Insider Cluster | $109.35 | awaiting T+60 | — | $88.61 (−18.97%) |
Sep 15, 2026 5w ago | Insider Cluster | $101.77 | awaiting T+60 | — | $88.61 (−12.93%) |
Sep 15, 2026 5w ago | 144 | $101.77 | awaiting T+60 | — | $88.61 (−12.93%) |
Sep 14, 2026 6w ago | 144 | $105.61 | awaiting T+60 | — | $88.61 (−16.10%) |
Sep 11, 2026 6w ago | 144 | $109.27 | awaiting T+60 | — | $88.61 (−18.91%) |
Sep 10, 2026 6w ago | Insider Cluster | $109.27 | awaiting T+60 | — | $88.61 (−18.91%) |
Sep 8, 2026 6w ago | Insider Cluster | $112.86 | awaiting T+60 | — | $88.61 (−21.49%) |
Sep 8, 2026 6w ago | Insider Buy | $112.86 | awaiting T+60 | — | $88.61 (−21.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers